SEND families 'frustrated and helpless'
Ofsted and the Care Quality Commission said both Wirral Council and the local NHS were failing young people who needed support.
The inspectors said that despite some progress having been made, urgent action needed to be taken.
Wirral Council said some improvements had been made but that not all families were feeling the benefit yet, the Local Democracy Reporting Service reported.
The inspection in January looked at both the services provided by Wirral Council as well as the NHS Cheshire and Merseyside Integrated Care Board.
It came after a highly critical inspection in 2021 and a government notice issued last year over a failure to make progress.
The council has invested more money in its special educational needs and disabilities (SEND) teams, and the Department for Education described the improvements as significant.
The January inspection, published recently, said there were long-standing failings "all too frequently characterised by waiting lists, and delays and failures to identify children and young people's needs".
The inspectors said: "Children and young people bear the consequences of weak systems for education, health and care (EHC) plans.
"Furthermore, many EHC plans are rarely, if ever, updated to reflect the reviews that education settings carry out.
"Consequently, these plans no longer reflect the needs of the children and young people concerned and their needs sometimes go unmet."
Wirral Council leader Paul Stuart, a member of the Local Area SEND Partnership Board, said: "We have made progress in recent months, which has been recognised by the Department for Education.
"While we continue to work across the partnership board to make large scale improvements for SEND children and their families, we recognise that these improvements are not yet consistently being felt by families themselves."
He said there were still changes needed to improve the services and provide positive outcomes for all children and young people across Wirral.
"We have a lot of work to do, but we're committed to our young people," he said. "There are a lot of dedicated and passionate staff across the partnership working hard to continue to drive that change and I'd thank them for their commitment to our borough and our young people.
"The momentum that Wirral's Local Area SEND Partnership has already built and the pace of work will continue to ensure that families feel the benefits of these changes and the needs of all children and young people with SEND across Wirral are met – and exceeded."
Simon Banks, place director (Wirral) for NHS Cheshire and Merseyside, said a recovery plan had been endorsed to improve wait times for assessments.
He added: "Wirral is an early adopter in the North West of a new neurodiversity profiling tool that will ensure that neurodevelopmental needs are identified early and support put in place across all areas of a child or young person's life."
Listen to the best of BBC Radio Merseyside on Sounds and follow BBC Merseyside on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.
Parents of SEND children accuse council of 'neglect'
Care Quality Commission
Ofsted
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
04-08-2025
- Yahoo
Encompass Health reports results for second quarter 2025
Increases full-year guidance BIRMINGHAM, Ala., Aug. 4, 2025 /PRNewswire/ -- Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the second quarter ended June 30, 2025. Summary resultsGrowthQ2 2025Q2 2024DollarsPercent(In Millions, Except Per Share Data) Net operating revenue $ 1,457.7$ 1,301.2$ 156.512.0 % Income from continuing operations attributable toEncompass Health per diluted share 1.401.130.2723.9 % Adjusted earnings per share 1.401.110.2926.1 % Cash flows provided by operating activities 270.2217.452.824.3 % Adjusted EBITDA 318.6271.846.817.2 % Adjusted free cash flow 185.9142.543.430.5 % (Actual Amounts)Discharges 65,23760,8337.2 % Same-store discharge growth 4.7 % Net patient revenue per discharge $ 21,670$ 20,8034.2 % See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure. Revenue growth of 12.0% resulted from increased discharges and pricing. Total discharges grew 7.2%, inclusive of same-store growth of 4.7%. Net patient revenue per discharge grew 4.2%. Cash flows provided by operating activities increased 24.3% to $270.2 million, primarily due to an increase in net income. Adjusted EBITDA increased 17.2% from increased revenue and expense leverage. "During the quarter, we further increased our capacity to serve patients in need of inpatient rehabilitation care, opening a new 60-bed hospital in Fort Myers, Florida, and adding 26 beds to an existing hospital," said President and Chief Executive Officer Mark Tarr. "Our clinical expertise and commitment to delivering high-quality, cost-effective care continues to benefit our patients, referral sources and payors." 2025 Guidance The Company increased its full-year guidance as follows:Full-Year 2025 GuidancePrevious GuidanceUpdated Guidance(In Millions, Except Per Share Data) Net operating revenue $5,850 to $5,925$5,880 to $5,980 Adjusted EBITDA $1,185 to $1,220$1,220 to $1,250 Adjusted earnings per share from continuing operationsattributable to Encompass Health $4.85 to $5.10$5.12 to $5.34 For considerations regarding the Company's 2025 guidance, see the supplemental information posted on the Company's website at See also the "Other information" section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share. Earnings conference call and webcast The Company will host an investor conference call at 10:00 a.m. Eastern Time on Tuesday, August 5, 2025 to discuss its results for the second quarter of 2025. For reference during the call, the Company will post certain supplemental information at The conference call may be accessed by dialing 800 343-4849 and giving the conference ID EHCQ225. International callers should dial 203 518-9848 and give the same conference ID. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at by clicking on an available link. About Encompass Health Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 169 hospitals in 38 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies™, and Forbes' Most Trusted Companies in America.1 For more information, visit or follow us on our newsroom, X, Instagram and Facebook. 1 Fortune © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is a trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license. Other information The information in this press release is summarized and should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the "June 2025 Form 10-Q"), when filed, as well as the Company's Current Report on Form 8-K filed on August 4, 2025 (the "Q2 Earnings Form 8-K"), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at for reference during its August 5, 2025 earnings call. The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company's adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q2 Earnings Form 8-K. Readers are encouraged to review the "Note Regarding Presentation of Non-GAAP Financial Measures" included in the Q2 Earnings Form 8-K which provides further explanation and disclosure regarding the Company's use of these non-GAAP financial measures. Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company's results computed in accordance with GAAP. However, the following reasonably estimable GAAP measures for 2025 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted: Interest expense and amortization of debt discounts and fees - approximately $125 million Amortization of debt-related items - approximately $10 million The Q2 Earnings Form 8-K and, when filed, the June 2025 Form 10-Q can be found on the Company's website at and the SEC's website at Encompass Health Corporation and SubsidiariesCondensed Consolidated Statements of Operations(Unaudited) Three Months Ended June 30,Six Months Ended June 30,2025202420252024(In Millions, Except Per Share Data) Net operating revenues $ 1,457.7$ 1,301.2$ 2,913.1$ 2,617.2 Operating expenses:Salaries and benefits 767.7700.51,530.01,412.1 Other operating expenses 213.8189.9431.3393.8 Occupancy costs 14.714.229.628.2 Supplies 63.157.6125.3116.1 General and administrative expenses 59.450.5111.7100.7 Depreciation and amortization 79.972.9159.1143.2 Total operating expenses 1,198.61,085.62,387.02,194.1 Interest expense and amortization of debt discounts and fees 30.434.362.269.5 Other income (6.7)(3.3)(9.2)(8.7) Equity in net income of nonconsolidated affiliates (1.4)(1.4)(2.3)(2.1) Income from continuing operations before income tax expense 236.8186.0475.4364.4 Provision for income tax expense 51.038.392.676.6 Income from continuing operations 185.8147.7382.8287.8 Loss from discontinued operations, net of tax (0.9)(1.2)(1.4)(2.5) Net income 184.9146.5381.4285.3 Less: Net income attributable to noncontrolling interests (42.8)(32.4)(87.8)(58.7) Net income attributable to Encompass Health $ 142.1$ 114.1$ 293.6$ 226.6 Weighted average common shares outstanding:Basic 100.699.9100.699.9 Diluted 102.3102.0102.2102.1 Earnings per common share:Basic earnings per share attributable to Encompass Health common shareholders:Continuing operations $ 1.42$ 1.14$ 2.92$ 2.28 Discontinued operations (0.01)(0.01)(0.01)(0.03) Net income $ 1.41$ 1.13$ 2.91$ 2.25 Diluted earnings per share attributable to Encompass Health common shareholders:Continuing operations $ 1.40$ 1.13$ 2.88$ 2.24 Discontinued operations (0.01)(0.01)(0.01)(0.02) Net income $ 1.39$ 1.12$ 2.87$ 2.22 Amounts attributable to Encompass Health common shareholders:Income from continuing operations $ 143.0$ 115.3$ 295.0$ 229.1 Loss from discontinued operations, net of tax (0.9)(1.2)(1.4)(2.5) Net income attributable to Encompass Health $ 142.1$ 114.1$ 293.6$ 226.6 Encompass Health Corporation and SubsidiariesCondensed Consolidated Balance Sheets(Unaudited) June 30, 2025December 31, 2024(In Millions) AssetsCurrent assets:Cash and cash equivalents $ 99.1$ 85.4 Restricted cash 38.337.7 Accounts receivable 612.5598.8 Other current assets 168.2165.0 Total current assets 918.1886.9 Property and equipment, net 3,820.33,643.1 Operating lease right-of-use assets 215.5203.7 Goodwill 1,303.01,284.0 Intangible assets, net 295.9297.8 Other long-term assets 232.9219.2 Total assets $ 6,785.7$ 6,534.7 Liabilities and Shareholders' EquityCurrent liabilities:Current portion of long-term debt $ 139.2$ 138.6 Current operating lease liabilities 25.526.3 Accounts payable 174.5171.0 Accrued expenses and other current liabilities 525.9505.1 Total current liabilities 865.1841.0 Long-term debt, net of current portion 2,320.32,359.2 Long-term operating lease liabilities 200.7189.7 Deferred income tax liabilities 110.6105.2 Other long-term liabilities 200.8190.4 Total liabilities 3,697.53,685.5 Commitments and contingenciesRedeemable noncontrolling interests 55.156.5 Shareholders' equity:Encompass Health shareholders' equity 2,280.12,067.0 Noncontrolling interests 753.0725.7 Total shareholders' equity 3,033.12,792.7 Total liabilities and shareholders' equity $ 6,785.7$ 6,534.7 Encompass Health Corporation and SubsidiariesCondensed Consolidated Statements of Cash Flows (Unaudited) Six Months Ended June 30,20252024(In Millions) Cash flows from operating activities:Net income $ 381.4$ 285.3 Loss from discontinued operations, net of tax 1.42.5 Adjustments to reconcile net income to net cash provided by operating activities—Depreciation and amortization 159.1143.2 Stock-based compensation 23.822.9 Deferred tax expense 5.34.2 Other, net 1.114.2 Change in assets and liabilities, net of acquisitions—Accounts receivable (15.7)0.9 Other assets (16.5)(48.4) Accounts payable (2.5)1.8 Other liabilities 23.332.3 Net cash used in operating activities of discontinued operations (1.9)(2.7) Total adjustments 176.0168.4 Net cash provided by operating activities 558.8456.2 Cash flows from investing activities:Purchases of property, equipment, and intangible assets (320.0)(296.3) Proceeds from sale of restricted investments 132.017.0 Purchases of restricted investments (127.8)(8.2) Other, net (8.1)(0.6) Net cash used in investing activities (323.9)(288.1) Cash flows from financing activities:Principal payments on debt, including pre-payments (10.7)(2.4) Borrowings on revolving credit facility 60.050.0 Payments on revolving credit facility (80.0)(50.0) Principal payments under finance lease obligations (11.6)(10.7) Repurchases of common stock, including fees and expenses (56.8)(16.8) Dividends paid on common stock (35.1)(30.8) Distributions paid to noncontrolling interests of consolidated affiliates (73.3)(52.5) Taxes paid on behalf of employees for shares withheld (19.9)(12.1) Contributions from noncontrolling interests of consolidated affiliates —33.3 Other, net 6.81.8 Net cash used in financing activities (220.6)(90.2) Increase in cash, cash equivalents, and restricted cash 14.377.9 Cash, cash equivalents, and restricted cash at beginning of period 123.1104.2 Cash, cash equivalents, and restricted cash at end of period $ 137.4$ 182.1 Encompass Health Corporation and SubsidiariesSupplemental InformationEarnings Per Share Three MonthsEnded June 30,Six MonthsEnded June 30,2025202420252024(In Millions, Except Per Share Data) Adjusted EBITDA $ 318.6$ 271.8$ 632.2$ 544.8 Depreciation and amortization (79.9)(72.9)(159.1)(143.2) Interest expense and amortization of debt discounts and fees (30.4)(34.3)(62.2)(69.5) Stock-based compensation (14.3)(13.6)(23.8)(22.9) (Loss) gain on disposal or impairment of assets (0.3)3.0(0.5)(10.7)193.7154.0386.6298.5 Items not indicative of ongoing operating performance:Change in fair market value of equity securities 0.3(0.4)1.0(0.1) Asset impairment impact on noncontrolling interests ———7.3 Pre-tax income 194.0153.6387.6305.7 Income tax expense (51.0)(38.3)(92.6)(76.6) Income from continuing operations (1) $ 143.0$ 115.3$ 295.0$ 229.1 Basic shares 100.699.9100.699.9 Diluted shares 102.3102.0102.2102.1 Basic earnings per share (1) $ 1.42$ 1.14$ 2.92$ 2.28 Diluted earnings per share (1) $ 1.40$ 1.13$ 2.88$ 2.24 (1) Income from continuing operations attributable to Encompass Health Encompass Health Corporation and SubsidiariesSupplemental InformationAdjusted Earnings Per Share Q26 Months2025202420252024 Earnings per share, as reported $ 1.40$ 1.13$ 2.88$ 2.24 Adjustments, net of tax:Asset impairment impact ———0.02 Income tax adjustments —(0.02)(0.11)(0.03) Change in fair market value of equity securities ——(0.01)— Adjusted earnings per share* $ 1.40$ 1.11$ 2.77$ 2.23* Adjusted EPS may not sum due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(In Millions) Net cash provided by operating activities $ 270.2$ 217.4$ 558.8$ 456.2 Interest expense and amortization of debt discounts and fees 30.434.362.269.5 Gain (loss) on sale of investments, excluding impairments 3.3(0.1)3.21.2 Equity in net income of nonconsolidated affiliates 1.41.42.32.1 Net income attributable to noncontrolling interests in continuing operations (42.8)(32.4)(87.8)(58.7) Amortization of debt-related items (2.4)(2.5)(4.8)(4.9) Distributions from nonconsolidated affiliates (0.9)(1.2)(1.4)(2.0) Current portion of income tax expense 54.540.687.372.4 Change in assets and liabilities 3.911.811.413.4 Cash used in operating activities of discontinued operations 1.22.01.92.7 Asset impairment impact on noncontrolling interests ———(7.3) Change in fair market value of equity securities (0.3)0.4(1.0)0.1 Other 0.10.10.10.1 Adjusted EBITDA $ 318.6$ 271.8$ 632.2$ 544.8 Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share For the Three Months Ended June 30, 2025AdjustmentsAs ReportedIncome Tax AdjustmentsChange in Fair Market Valueof Equity SecuritiesAs Adjusted(In Millions, Except Per Share Amounts) Adjusted EBITDA* $ 318.6$ —$ —$ 318.6 Depreciation and amortization (79.9)——(79.9) Interest expense and amortization of debt discounts and fees (30.4)——(30.4) Stock-based compensation (14.3)——(14.3) Loss on disposal or impairment of assets (0.3)——(0.3) Change in fair market value of equity securities 0.3—(0.3)— Income from continuing operations before income tax expense 194.0—(0.3)193.7 Provision for income tax expense (51.0)0.40.1(50.5) Income from continuing operations attributable to Encompass Health $ 143.0$ 0.4$ (0.2)$ 143.2 Diluted earnings per share from continuing operations** $ 1.40$ —$ —$ 1.40 Diluted shares used in calculation 102.3* See reconciliation of net income to Adjusted EBITDA. ** Adjusted EPS may not sum across due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per ShareFor the Three Months Ended June 30, 2024AdjustmentsAs ReportedIncome TaxAdjustmentsChange in FairMarket Valueof Equity SecuritiesAsAdjusted(In Millions, Except Per Share Amounts) Adjusted EBITDA* $ 271.8$ —$ —$ 271.8 Depreciation and amortization (72.9)——(72.9) Interest expense and amortization of debt discounts and fees (34.3)——(34.3) Stock-based compensation (13.6)——(13.6) Gain on disposal or impairment of assets 3.0——3.0 Change in fair market value of equity securities (0.4)—0.4— Income from continuing operations before income tax expense 153.6—0.4154.0 Provision for income tax expense (38.3)(2.4)(0.1)(40.8) Income from continuing operations attributable to Encompass Health $ 115.3$ (2.4)$ 0.3$ 113.2 Diluted earnings per share from continuing operations** $ 1.13$ (0.02)$ —$ 1.11 Diluted shares used in calculation 102.0* See reconciliation of net income to Adjusted EBITDA. ** Adjusted EPS may not sum across due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share For the Six Months Ended June 30, 2025AdjustmentsAs ReportedIncome TaxAdjustmentsChange in FairMarket Valueof Equity SecuritiesAsAdjusted(In Millions, Except Per Share Amounts) Adjusted EBITDA* $ 632.2$ —$ —$ 632.2 Depreciation and amortization (159.1)——(159.1) Interest expense and amortization of debt discounts and fees (62.2)——(62.2) Stock-based compensation (23.8)——(23.8) Loss on disposal or impairment of assets (0.5)——(0.5) Change in fair market value of equity securities 1.0—(1.0)— Income from continuing operations before income tax expense 387.6—(1.0)386.6 Provision for income tax expense (92.6)(11.6)0.3(103.9) Income from continuing operations attributable to Encompass Health $ 295.0$ (11.6)$ (0.7)$ 282.7 Diluted earnings per share from continuing operations** $ 2.88$ (0.11)$ (0.01)$ 2.77 Diluted shares used in calculation 102.2* See reconciliation of net income to Adjusted EBITDA. ** Adjusted EPS may not sum across due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share For the Six Months Ended June 30, 2024AdjustmentsAs Reported AssetImpairmentImpactIncome Tax AdjustmentsChange in FairMarket Valueof EquitySecuritiesAs Adjusted(In Millions, Except Per Share Amounts) Adjusted EBITDA* $ 544.8 $ —$ —$ —$ 544.8 Depreciation and amortization (143.2) ———(143.2) Interest expense and amortization of debt discounts and fees (69.5) ———(69.5) Stock-based compensation (22.9) ———(22.9) Loss on disposal or impairment of assets (10.7) 10.4——(0.3) Change in fair market value of equity securities (0.1) ——0.1— Asset impairment impact on noncontrolling interests 7.3 (7.3)——— Income from continuing operations before income tax expense 305.7 3.1—0.1308.9 Provision for income tax expense (76.6) (1.3)(3.0)—(80.9) Income from continuing operations attributable to Encompass Health $ 229.1 $ 1.8$ (3.0)$ 0.1$ 228.0 Diluted earnings per share from continuing operations** $ 2.24 $ 0.02$ (0.03)$ —$ 2.23 Diluted shares used in calculation 102.1 * See reconciliation of net income to Adjusted EBITDA. ** Adjusted EPS may not sum across due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Net Income to Adjusted EBITDA Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(In Millions) Net income $ 184.9$ 146.5$ 381.4$ 285.3 Loss from discontinued operations, net of tax, attributable to Encompass Health 0.91.21.42.5 Net income attributable to noncontrolling interests included in continuing operations (42.8)(32.4)(87.8)(58.7) Provision for income tax expense 51.038.392.676.6 Interest expense and amortization of debt discounts and fees 30.434.362.269.5 Depreciation and amortization 79.972.9159.1143.2 Loss (gain) on disposal or impairment of assets 0.3(3.0)0.510.7 Stock-based compensation 14.313.623.822.9 Change in fair market value of equity securities (0.3)0.4(1.0)0.1 Asset impairment impact on noncontrolling interests ———(7.3) Adjusted EBITDA $ 318.6$ 271.8$ 632.2$ 544.8 Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow Three Months EndedJune 30,Six Months Ended June 30,2025202420252024(In Millions) Net cash provided by operating activities $ 270.2$ 217.4$ 558.8$ 456.2 Impact of discontinued operations 1.22.01.92.7 Net cash provided by operating activities of continuing operations 271.4219.4560.7458.9 Capital expenditures for maintenance (45.1)(48.9)(79.1)(87.6) Distributions paid to noncontrolling interests of consolidated affiliates (40.4)(27.8)(73.3)(52.5) Items not indicative of ongoing operating performance:Transaction costs and related liabilities —(0.2)—(8.7) Adjusted free cash flow $ 185.9$ 142.5$ 408.3$ 310.1 For the three months ended June 30, 2025, net cash used in investing activities was $165.4 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended June 30, 2025 was $90.2 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, repurchases of common stock, net debt payments, and cash dividends paid on common stock. For the three months ended June 30, 2024, net cash used in investing activities was $158.4 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended June 30, 2024 was $49.6 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and repurchases of common stock partially offset by contributions from noncontrolling interests of consolidated affiliates. For the six months ended June 30, 2025, net cash used in investing activities was $323.9 million and resulted primarily from capital expenditures. Net cash used in financing activities during the six months ended June 30, 2025 was $220.6 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, repurchases of common stock, net debt payments, and cash dividends paid on common stock. For the six months ended June 30, 2024, net cash used in investing activities was $288.1 million and resulted primarily from capital expenditures. Net cash used in financing activities during the six months ended June 30, 2024 was $90.2 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and repurchases of common stock partially offset by contributions from noncontrolling interests of consolidated affiliates. Encompass Health Corporation and SubsidiariesForward-Looking Statements Statements contained in this press release and the supplemental information which are not historical facts, such as those relating to the business, strategy, outlook, growth targets and guidance considerations, dividend strategies, effective income tax rates, cost trends, legislative and regulatory developments or their impacts, financial guidance, ability to return value to shareholders, projected capital expenditures, acquisition opportunities, development projects, addressable market size, other balance sheet and cash flow plans, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, infectious disease outbreak, including the speed, depth, geographic reach and duration of its spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; Encompass Health's infectious disease prevention and control efforts; the demand for Encompass Health's services, including based on any downturns in the economy, consumer confidence, or the capital markets; the price of Encompass Health's common stock as it affects Encompass Health's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or its vendors' or partners' information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; Encompass Health's ability to realize construction time and cost savings from prefabrication of hospitals; increases in Medicare audit activity, including increased use of sampling and extrapolation, resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction and Encompass Health's ability to adapt operations to those changes, including in connection with the CMS inpatient rehabilitation review choice demonstration project; competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and retain favorable arrangements with third-party payors; Encompass Health's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis; Encompass Health's ability to adapt to changes in the healthcare delivery system, including value-based purchasing and involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, which may be worsened by infectious disease outbreaks, and the impact on Encompass Health's labor expenses from potential union activity, staffing shortages, and competitive compensation practices; general conditions in the economy and capital markets, including any instability or uncertainty related to trade war, armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; the increase in the cost of, or the decrease in the availability of, construction materials and necessary supplies, including as a result of tariffs and import restrictions; the increase in the costs of defending and insuring against alleged professional liability claims, and Encompass Health's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10‑K for the year ended December 31, 2024 and Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, when filed. Media ContactPolly Manuel, 205 Investor Relations ContactMark Miller, 205 View original content to download multimedia: SOURCE Encompass Health Corp.
Business Insider
19-07-2025
- Business Insider
Encompass to build 40-bed inpatient rehabilitation hospital in Tennessee
Encompass Health (EHC) announced plans to build a freestanding, 40-bed inpatient rehabilitation hospital in Cleveland, Tennessee as a satellite location of Encompass Health Rehabilitation Hospital of Chattanooga. 'We are excited to add another Encompass Health location in the greater Chattanooga area,' said Abe Sims, president of Encompass Health's MidAtlantic region. 'We look forward to serving patients in Cleveland and surrounding communities with high-quality, compassionate inpatient rehabilitative care, close to home.' The hospital is expected to open in 2026 and will be part of Encompass Health's national network of inpatient rehabilitation hospitals, the company added. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Medscape
15-07-2025
- Medscape
Adjuvant Triple Therapy Boosts Survival in Biliary Cancers
TOPLINE: Camrelizumab plus concurrent capecitabine and radiotherapy (combination treatment) improved overall survival (OS) and recurrence-free survival in patients with resectable extrahepatic cholangiocarcinoma (EHC) and gallbladder cancer. METHODOLOGY: Patients with EHC and gallbladder cancer have a high recurrence rate and poor survival after surgery. Existing adjuvant therapies provide limited benefit, underscoring the need for novel treatment combinations. This multicenter, randomized clinical trial investigated the safety and efficacy of chemoradiation with anti-PD-1 immunotherapy in these patients. A total of 93 patients with histologically confirmed EHC or gallbladder cancer (median age, 62 years; 52% women) who underwent curative resection with stage pT2-4 or N1M0 disease were randomly assigned to either the combination treatment group (n = 46) or the observation group (no anticancer treatment unless relapse was detected; n = 47). Those in the combination treatment group received 200 mg camrelizumab intravenously every 3 weeks, followed by concurrent 1330 mg/m 2 oral capecitabine twice daily with radiotherapy (45 Gy in 25 fractions for lymph nodes and 52.5-55.0 Gy for tumor beds). oral capecitabine twice daily with radiotherapy (45 Gy in 25 fractions for lymph nodes and 52.5-55.0 Gy for tumor beds). The primary endpoint was OS, and secondary endpoints were recurrence-free survival and adverse events (AEs). The median follow-up duration was 36 months. TAKEAWAY: The combination treatment significantly improved OS (hazard ratio [HR], 0.43; P = .004), with 3-year OS rate of 58.2% vs 30.5% in the observation group. The median recurrence-free survival was longer in the combination treatment group than in the observation group (26 months vs 13 months; HR, 0.46; P < .001), with the 3-year recurrence-free survival rate of 40.3% vs 17.2%. No treatment-related deaths were observed. The most common severe AEs of grade 3 or 4 were anemia (15%), radiation-associated dermatitis (11%), nausea (11%), and hand-foot syndrome (4%) in the combination group and anemia (4%), fatigue (4%), and neutropenia (4%) in the observation group. Subgroup analyses suggested patients with EHC vs gallbladder cancer and those with an Eastern Cooperative Oncology Group score of 0 and tumors ≤ 5 cm were more likely to benefit from the combination treatment. IN PRACTICE: 'We congratulate the authors for conducting and reporting an important clinical trial that moves the field forward. Considering the current level of evidence used to guide patient management after resection, we suspect this regimen may be adopted into practice even prior to the conduct of a phase 3 trial,' Edgar Ben-Josef, MD, University of Pennsylvania, Philadelphia, wrote, in an invited commentary on the new research published in JAMA Oncology. 'However, we would caution that this study should be viewed not as an ending but as a building block toward studies that demonstrate an even greater level of confidence [in] more effective adjuvant regimens for patients with biliary cancers. SOURCE: The study, led by Han Xiao, MD, The First Affiliated Hospital of Sun Yat-sen University in Guangzhou, China, was published online in JAMA Oncology. LIMITATIONS: This study was only conducted on Chinese patients, limiting generalizability to Western populations. Although the study met the predefined 2-year follow-up for all patients, both groups showed better-than-expected OS rates, resulting in fewer endpoint events than anticipated. Additionally, the open-label design and the combination of multiple treatments might have confounded efficacy assessment for each treatment component. DISCLOSURES: This study received project grants from the National Natural Science Foundation of China and the Science and Technology Program of Guangzhou. The authors reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
